
爱萨尔生物
爱萨尔生物
Biotech/Healthcare
Shanghai IxCell Biotechnology Co., Ltd.’s founding team comes from U.S. research institutions focused on induced pluripotent stem cells, including the University of Wisconsin–Madison, where iPSC technology originated, as well as U.S.
Latest round: Series A (2022)
Source: ChinaBulls — chinabulls.com
Last updated 2022-09-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.